[
  {
    "ts": null,
    "headline": "Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight",
    "summary": "The 67th American Society of Hematology (ASH) Annual Meeting, held December 6-9, 2025, in Orlando, Florida, showcased groundbreaking clinical advances in multiple myeloma treatment from leading biopharmaceutical companies. The conference featured unprecedented efficacy data demonstrating potential functional cures and innovative approaches across novel immunotherapies, bispecific antibodies, and next-generation targeted agents, signaling a major shift in how the disease is managed.",
    "url": "https://finnhub.io/api/news?id=6fdd21760a3d9cddf4caa3409f50674a1cbfac444dcdba2abccc6b56310ee9cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765492260,
      "headline": "Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight",
      "id": 137766873,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The 67th American Society of Hematology (ASH) Annual Meeting, held December 6-9, 2025, in Orlando, Florida, showcased groundbreaking clinical advances in multiple myeloma treatment from leading biopharmaceutical companies. The conference featured unprecedented efficacy data demonstrating potential functional cures and innovative approaches across novel immunotherapies, bispecific antibodies, and next-generation targeted agents, signaling a major shift in how the disease is managed.",
      "url": "https://finnhub.io/api/news?id=6fdd21760a3d9cddf4caa3409f50674a1cbfac444dcdba2abccc6b56310ee9cd"
    }
  },
  {
    "ts": null,
    "headline": "Botox maker quietly launches plan to fend off rivals",
    "summary": "Botox has become so synonymous with anti-aging wrinkle treatments that many people use the name the same way they refer to tissues as Kleenex. But the brand power has a downside: Competitors have flooded the market, prices have dropped, and the company behind Botox is now making aggressive moves to ...",
    "url": "https://finnhub.io/api/news?id=0cbb5e3a4775de8ffdfcd125ea27d0bcd448c269258f5da9690e11203822e997",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765475125,
      "headline": "Botox maker quietly launches plan to fend off rivals",
      "id": 137759759,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Botox has become so synonymous with anti-aging wrinkle treatments that many people use the name the same way they refer to tissues as Kleenex. But the brand power has a downside: Competitors have flooded the market, prices have dropped, and the company behind Botox is now making aggressive moves to ...",
      "url": "https://finnhub.io/api/news?id=0cbb5e3a4775de8ffdfcd125ea27d0bcd448c269258f5da9690e11203822e997"
    }
  },
  {
    "ts": null,
    "headline": "Is AbbVie Stock Too Cheap to Ignore at Today's Price?",
    "summary": "The drugmaker has plenty to offer investors.",
    "url": "https://finnhub.io/api/news?id=577e792498ab7f0f61068a0bb7bbf14e02f57d431d910ca6caf8bdec98fb02f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765470360,
      "headline": "Is AbbVie Stock Too Cheap to Ignore at Today's Price?",
      "id": 137758763,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The drugmaker has plenty to offer investors.",
      "url": "https://finnhub.io/api/news?id=577e792498ab7f0f61068a0bb7bbf14e02f57d431d910ca6caf8bdec98fb02f6"
    }
  },
  {
    "ts": null,
    "headline": "$73 Billion Non-Opioid Therapeutics Industry Assessment, 2032 Featuring AbbVie, GlaxoSmithKline, Acorda Therapeutics, Allay Therapeutics, Alnylam Pharmaceuticals and Other Key Players",
    "summary": "The Non-Opioid Therapeutics Market is rapidly expanding due to increased demand for safer pain management Non-Opioid Therapeutics Market Non-Opioid Therapeutics Market Dublin, Dec. 11, 2025 (GLOBE NEWSWIRE) -- The \"Non-Opioid Therapeutics Market - Global Forecast 2025-2032\" has been added to ResearchAndMarkets.com's offering. This market research report focuses on the evolving landscape of the Non-Opioid Therapeutics Market. This sector has grown from USD 40.77 billion in 2024 to USD 43.78 billi",
    "url": "https://finnhub.io/api/news?id=be87fc19972eb016023bea935a7d78fc206e0179c4e768116ea4749da18770cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765469940,
      "headline": "$73 Billion Non-Opioid Therapeutics Industry Assessment, 2032 Featuring AbbVie, GlaxoSmithKline, Acorda Therapeutics, Allay Therapeutics, Alnylam Pharmaceuticals and Other Key Players",
      "id": 137758764,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The Non-Opioid Therapeutics Market is rapidly expanding due to increased demand for safer pain management Non-Opioid Therapeutics Market Non-Opioid Therapeutics Market Dublin, Dec. 11, 2025 (GLOBE NEWSWIRE) -- The \"Non-Opioid Therapeutics Market - Global Forecast 2025-2032\" has been added to ResearchAndMarkets.com's offering. This market research report focuses on the evolving landscape of the Non-Opioid Therapeutics Market. This sector has grown from USD 40.77 billion in 2024 to USD 43.78 billi",
      "url": "https://finnhub.io/api/news?id=be87fc19972eb016023bea935a7d78fc206e0179c4e768116ea4749da18770cb"
    }
  },
  {
    "ts": null,
    "headline": "Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth",
    "summary": "ABBV's expanding oncology lineup, spanning new solid tumor drugs and rising Venclexta sales, is helping drive steady top-line growth.",
    "url": "https://finnhub.io/api/news?id=459633750c779e958ca55188494098065f13895a77f80751d607045aecd2558c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765457340,
      "headline": "Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth",
      "id": 137757905,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ABBV's expanding oncology lineup, spanning new solid tumor drugs and rising Venclexta sales, is helping drive steady top-line growth.",
      "url": "https://finnhub.io/api/news?id=459633750c779e958ca55188494098065f13895a77f80751d607045aecd2558c"
    }
  },
  {
    "ts": null,
    "headline": "HSBC Upgrades AbbVie (ABBV) to Buy, Raises Price Target to $265",
    "summary": "AbbVie Inc. (NYSE:ABBV) is included among the 15 Best Stocks to Buy for the Long Term. On December 10, HSBC increased its price target on AbbVie Inc. (NYSE:ABBV) from $225 to $265 and also upgraded the stock to Buy. Previously, on November 5, Piper Sandler reiterated a Buy rating on ABBV with a $289 price […]",
    "url": "https://finnhub.io/api/news?id=87af44004b17ae0091ead4b6cf066fcd369c4d40fc3ae377c3289fb2894770cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765439260,
      "headline": "HSBC Upgrades AbbVie (ABBV) to Buy, Raises Price Target to $265",
      "id": 137755875,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) is included among the 15 Best Stocks to Buy for the Long Term. On December 10, HSBC increased its price target on AbbVie Inc. (NYSE:ABBV) from $225 to $265 and also upgraded the stock to Buy. Previously, on November 5, Piper Sandler reiterated a Buy rating on ABBV with a $289 price […]",
      "url": "https://finnhub.io/api/news?id=87af44004b17ae0091ead4b6cf066fcd369c4d40fc3ae377c3289fb2894770cf"
    }
  },
  {
    "ts": null,
    "headline": "10 High-Yielding Dividend Stocks to Buy for 2026",
    "summary": "A stronger economy and Fed rate cuts could provide tailwinds for dividend stocks next year. Consider buying names such as AbbVie, FedEx, and Coca-Cola.",
    "url": "https://finnhub.io/api/news?id=d1092876231959dbff8f287490a09ba9ec791e01dbcb315ced91f09f7e38fc96",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765438200,
      "headline": "10 High-Yielding Dividend Stocks to Buy for 2026",
      "id": 137755844,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "A stronger economy and Fed rate cuts could provide tailwinds for dividend stocks next year. Consider buying names such as AbbVie, FedEx, and Coca-Cola.",
      "url": "https://finnhub.io/api/news?id=d1092876231959dbff8f287490a09ba9ec791e01dbcb315ced91f09f7e38fc96"
    }
  }
]